Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats.

View at publisher
Authors: Bryan W. Jenkins, Cerina Pang, Robbie Y. Kuang, Elise M. Weerts, Catherine F. Moore
Cited by: 1

Abstract

= 100, 50% female) were administered escalating doses of morphine across 10 days (10-50 mg/kg, twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to Day 7) timepoints. Rats were treated daily with oral CBD (10 or 30 mg/kg, p.o.) or sesame oil vehicle, beginning 14-hr after their final morphine or saline injection. Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), pain sensitivity, and measurements of anxiety-like behaviors in the protracted phase. Compared to nondependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). In the protracted phase, limited withdrawal signs and no anxiety-like behaviors were detected. Oral CBD did not affect symptoms of opioid withdrawal. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

Fields of Study & Subjects

Cannabis and Cannabinoid Research Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Publication details

Journal / source
Experimental and Clinical Psychopharmacology
Publisher
American Psychological Association (APA)
Volume
34
Issue
4
Pages
408–416
Publication date
12 January 2026
Language
EN